Novartis applies for second Kymriah indication

Swiss drugmaker Novartis (NOVN: VX) is bidding to extend the marketable use of Kymriah (tisagenlecleucel), to include B-cell lymphoma (DLBCL) patients.

The regulatory filing includes adult patients with relapsed or refractory forms of the disease who are ineligible for autologous stem cell transplants.

If approved, the submission to the US Food and Drug Administration would hand Novartis the second indication for its historic CAR T-Cell therapy, following its approval earlier in the year for B-cell precursor acute lymphoblastic leukemia (ALL).